Kazia Therapeutics launches registered public offering of ADSs and warrants
KZIA•Use of proceeds and underwriting
Net proceeds are earmarked mainly for paxalisib clinical development in TNBC, HR+/HER2- breast cancer, other oncology studies, and working capital.
Leerink Partners and Guggenheim Securities were named joint bookrunners. Offering size, pricing, and timing have not been set.
Kazia announces registered public offering
Kazia Therapeutics launched a tranched registered public offering of ADSs, or pre-funded warrants in lieu of ADSs.
The deal includes Series A warrants priced at 115% of the offering price, expiring after the Stage IV TNBC readout or five years.
Series B warrants are priced at 125% of the offering price, expiring after the HR+/HER2- readout or five years.
